Dynamic Hydroxypiperidine Resolution for BTK Inhibitor Synthesis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for synthesizing chiral hydroxypiperidine intermediates for Btk inhibitors like ibrutinib face limitations in yield and selectivity, particularly in enzymatic kinetic resolutions, which often result in less than 50% theoretical yield and specific stereochemistry configurations.
Innovation Solution
An enzymatic kinetic resolution process using a suitable enzyme and an acyl donor in the presence of a racemisation catalyst, achieving dynamic kinetic resolution to produce an enantioenriched compound of formula (I) with greater than 20% enantiomeric excess, preferably using proteases or lipases like Subtilisin or Candida rugosa lipase, and acyl donors such as butyrate, in solvents like toluene or methyl-THF.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If enzymatic kinetic resolution is used to prepare chiral hydroxypiperidine, then enantiomeric excess can be achieved, but the theoretical yield is limited to less than 50%
Solution Approach 1:
The patent applies dynamic kinetic resolution by combining enzymatic kinetic resolution with in-situ racemization. The system dynamically converts the unreacted enantiomer back to the racemic mixture through racemization catalysts (transition metal complexes or organocatalysts), allowing continuous conversion beyond the 50% yield limitation of static kinetic resolution. This dynamic process enables theoretical yields exceeding 50% while maintaining high enantiomeric excess.
Solution Approach 2:
The patent implements continuous useful action by integrating the racemization step into the kinetic resolution process. As the enzymatic reaction proceeds and one enantiomer is consumed, the racemization catalyst continuously regenerates the reactive enantiomer from the product or unreacted material, maintaining continuous conversion and preventing the reaction from stalling at 50% conversion. This continuous cycle of resolution and racemization drives the reaction to high conversion and yield.
2Ease of manufacture
If conventional enzymatic resolution is used, then process simplicity is maintained, but enantiomeric excess and conversion are limited
Solution Approach 1:
The patent merges two distinct processes - enzymatic kinetic resolution and chemical/racemization - into a single integrated dynamic kinetic resolution process. By combining the enzyme-catalyzed enantioselective reaction with in-situ racemization using transition metal complexes or organocatalysts, the system achieves both high enantiomeric excess and high conversion in one pot, rather than requiring separate resolution and racemization steps. This merging maintains relative process simplicity while dramatically improving manufacturing precision.
Solution Approach 2:
The patent employs parameter changes by adjusting reaction conditions (temperature, solvent, catalyst loading, substrate concentration) to optimize both the enzymatic resolution and the racemization rates. By carefully controlling these parameters, the system achieves the optimal balance between enantioselectivity and conversion, pushing the theoretical yield beyond 50% while maintaining high enantiomeric excess. Parameter optimization allows the coupled system to outperform either process alone.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The process achieves high enantiomeric excess (up to 98%) and conversion rates (up to 50%) of the desired (S)-configuration compound, suitable for further synthesis of Btk inhibitors like ibrutinib, enhancing the efficiency and selectivity of the synthesis.
Implementation Method 1
enzymatic kinetic resolution of a compound of formula (II) wherein R1 represents hydrogen and R2 is as defined above
Implementation Method 2
enzymatic kinetic resolution... in the presence of an acyl donor
Implementation Method 3
dynamic kinetic resolutions may overcome the yield limitation by racemising the remaining unreacted enantiomer
Data Source
AI summary
Disclosed is a process for the preparation of certain intermediates, e.g. the following compound:which intermediate and processes are useful in the preparation of a BTK inhibitor, such as ibrutinib.